Traws Pharma CFO Mark Guerin resigns; Nora Brennan named Interim CFO

Traws Pharma, Inc.

Mark Guerin resigned as CFO effective Feb 5, 2025; receives $250K in 9 monthly installments plus $150K lump sum.
Guerin gets $75K RSUs vesting over 2 years, accelerated vesting of all outstanding awards, option exercise extended to Feb 2026.
Nora Brennan appointed Interim CFO effective Feb 5; compensation $42K/month through July 5, 2025.
Brennan previously CFO at Spectrum Pharmaceuticals and TELA Bio; led TELA Bio through IPO.
If extended after July 5, Brennan eligible for $425K salary, 115K RSUs, and target bonus up to 50% of salary.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Guerin

Chief Financial Officer

TRAW · Traws Pharma, Inc.

Effective: 2025-02-05
Successor: Nora Brennan
Filed: February 7, 2025, 6:59 PM ET

On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.

Appointed (interim)

Nora Brennan

Interim Chief Financial Officer

TRAW · Traws Pharma, Inc.

Effective: 2025-02-05
Filed: February 7, 2025, 6:59 PM ET

On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Guerin resigned as Chief Financial Officer at Traws Pharma, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Nora Brennan was appointed as Interim Chief Financial Officer at Traws Pharma, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.

View on SEC.gov

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-010580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.